Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
Discovered in 1973 by biochemist Loren Pickart in human blood plasma, this copper-tripeptide has been the subject of over five decades of research that has progressively revealed the breadth of its biological functions
Successful therapeutic peptides in this category often show high selectivity for their target enzymes while maintaining appropriate pharmacokinetic properties for clinical use
The consensus: at physiological doses with proper monitoring, cardiovascular risk is manageable
The amyloidogenic core sequence of hIAPP (residues 2029, known as the FGAILS region) has been substituted to eliminate -sheet aggregation propensitya critical requirement for generating a stable, injectable research compound
If tendon pain, joint irritation, or muscle strain limits training, hypertrophy progress can stall
US$ 26.72
US$ 21.24
US$ 24.06
US$ 22.19
US$ 23.50
US$ 22.38
US$ 21.03
US$ 23.16
US$ 25.19
US$ 21.85
US$ 27.82